147 related articles for article (PubMed ID: 14968121)
1. Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta.
Yanagawa T; Watanabe H; Takeuchi T; Fujimoto S; Kurihara H; Takagishi K
Lab Invest; 2004 Apr; 84(4):513-22. PubMed ID: 14968121
[TBL] [Abstract][Full Text] [Related]
2. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells.
Niinaka Y; Paku S; Haga A; Watanabe H; Raz A
Cancer Res; 1998 Jun; 58(12):2667-74. PubMed ID: 9635595
[TBL] [Abstract][Full Text] [Related]
3. AMF/G6PI induces differentiation of leukemic cells via an unknown receptor that differs from gp78.
Haga A; Komazaki S; Funasaka T; Hashimoto K; Yokoyama Y; Watanabe H; Raz A; Nagase H
Leuk Lymphoma; 2006 Oct; 47(10):2234-43. PubMed ID: 17071500
[TBL] [Abstract][Full Text] [Related]
4. [Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm].
Haga A
Yakugaku Zasshi; 2005 Feb; 125(2):169-75. PubMed ID: 15684571
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide.
Watanabe H; Takehana K; Date M; Shinozaki T; Raz A
Cancer Res; 1996 Jul; 56(13):2960-3. PubMed ID: 8674049
[TBL] [Abstract][Full Text] [Related]
6. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins.
Torimura T; Ueno T; Kin M; Harada R; Nakamura T; Kawaguchi T; Harada M; Kumashiro R; Watanabe H; Avraham R; Sata M
Hepatology; 2001 Jul; 34(1):62-71. PubMed ID: 11431735
[TBL] [Abstract][Full Text] [Related]
7. Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein.
Haga A; Niinaka Y; Raz A
Biochim Biophys Acta; 2000 Jul; 1480(1-2):235-44. PubMed ID: 11004567
[TBL] [Abstract][Full Text] [Related]
8. Autocrine motility factor signaling enhances pancreatic cancer metastasis.
Tsutsumi S; Yanagawa T; Shimura T; Kuwano H; Raz A
Clin Cancer Res; 2004 Nov; 10(22):7775-84. PubMed ID: 15570012
[TBL] [Abstract][Full Text] [Related]
9. Expression of autocrine motility factor/phosphohexose isomerase in Cos7 cells.
Lagana A; Duchaine T; Raz A; DesGroseillers L; Nabi IR
Biochem Biophys Res Commun; 2000 Jun; 273(1):213-8. PubMed ID: 10873589
[TBL] [Abstract][Full Text] [Related]
10. Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Yanagawa T; Funasaka T; Tsutsumi S; Watanabe H; Raz A
Endocr Relat Cancer; 2004 Dec; 11(4):749-59. PubMed ID: 15613449
[TBL] [Abstract][Full Text] [Related]
11. Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: human melanoma and ras-transfected NIH3T3 cells.
Seiki M; Sato H; Liotta LA; Schiffmann E
Int J Cancer; 1991 Nov; 49(5):717-20. PubMed ID: 1657797
[TBL] [Abstract][Full Text] [Related]
12. Autocrine motility factor and its receptor: role in cell locomotion and metastasis.
Nabi IR; Watanabe H; Raz A
Cancer Metastasis Rev; 1992 Mar; 11(1):5-20. PubMed ID: 1324804
[TBL] [Abstract][Full Text] [Related]
13. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis.
Niinaka Y; Harada K; Fujimuro M; Oda M; Haga A; Hosoki M; Uzawa N; Arai N; Yamaguchi S; Yamashiro M; Raz A
Cancer Res; 2010 Nov; 70(22):9483-93. PubMed ID: 20978190
[TBL] [Abstract][Full Text] [Related]
14. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression.
Haga A; Funasaka T; Niinaka Y; Raz A; Nagase H
Int J Cancer; 2003 Dec; 107(5):707-14. PubMed ID: 14566819
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Funasaka T; Hu H; Yanagawa T; Hogan V; Raz A
Cancer Res; 2007 May; 67(9):4236-43. PubMed ID: 17483335
[TBL] [Abstract][Full Text] [Related]
16. [The role of autocrine motility factor receptor in metastasis].
Watanabe H; Chigira M; Raz A
Gan To Kagaku Ryoho; 1993 Feb; 20(3):405-9. PubMed ID: 8382466
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell autocrine motility factor receptor.
Nabi IR; Watanabe H; Silletti S; Raz A
EXS; 1991; 59():163-77. PubMed ID: 1655517
[TBL] [Abstract][Full Text] [Related]
18. Autocrine motility factor (neuroleukin, phosphohexose isomerase) induces cell movement through 12-lipoxygenase-dependent tyrosine phosphorylation and serine dephosphorylation events.
Timár J; Tóth S; Tóvári J; Paku S; Raz A
Clin Exp Metastasis; 1999; 17(10):809-16. PubMed ID: 11089878
[TBL] [Abstract][Full Text] [Related]
19. Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells.
Silletti S; Yao JP; Pienta KJ; Raz A
Int J Cancer; 1995 Sep; 63(1):100-5. PubMed ID: 7558435
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motility factor.
Nakajima K; Yanagawa T; Watanabe H; Takagishi K
Oncol Rep; 2012 Dec; 28(6):1953-8. PubMed ID: 23027359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
